No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Ixempra (ixabepilone) is a chemotherapy drug used to treat metastatic breast cancer. It is a semi-synthetic derivative of epothilone B, a natural product isolated from the bacterium Sorangium cellulosum. Ixempra is administered intravenously and works by inhibiting the growth of cancer cells. It is approved for use in combination with capecitabine, a chemotherapy drug, for the treatment of metastatic breast cancer in patients who have received at least two prior chemotherapy regimens.
Ixempra is marketed by Bristol-Myers Squibb, a global biopharmaceutical company. The drug is available in the United States, Canada, Europe, Australia, and other countries. Other companies involved in the Ixempra market include Pfizer, Merck, and AstraZeneca. Show Less Read more
